Biologics Contract Market

Contract manufacturing is a type of outsourcing in which a company enters into an agreement or legal agreement for a product, part or component with another manufacturing company, who then uses that agreement or legal settlement of the product in its production process. This involves the manufacture of biopharmaceutical molecules, proteins, nucleic acids, blood components and vaccines developed from biological sources. These companies specialize in the production of molecules and provide different types of services such as development processes, analysis, and quality control.
Biologics Contract Market contains market size and forecasts of Biologics Contract Manufacturing in Global, including the following market information:
Global Biologics Contract Manufacturing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Biologics Contract Manufacturing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biologics Contract Manufacturing include Lonza Group, Samsung Biologics Co., Ltd., Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Fujifilm Holding Corporation, AbbVie, Inc., Boehringer Ingelheim and Recipharm Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Biologics Contract Manufacturing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biologics Contract Manufacturing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Biologics Contract Manufacturing Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Molecular Therapy
Others
Global Biologics Contract Manufacturing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Biologics Contract Manufacturing Market Segment Percentages, by Application, 2021 (%)
Medical Company
Hospital
Global Biologics Contract Manufacturing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Biologics Contract Manufacturing Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biologics Contract Manufacturing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Biologics Contract Manufacturing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lonza Group
Samsung Biologics Co., Ltd.
Thermo Fisher Scientific, Inc.
Cambrex Corporation
Siegfried Holding AG
Fujifilm Holding Corporation
AbbVie, Inc.
Boehringer Ingelheim
Recipharm Pharmaceuticals
WuXi Biologics
Catalent, Inc.